Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Notes Payables (2019 - 2024)

Immunocore Holdings (IMCR) has disclosed Notes Payables for 2 consecutive years, with $48.2 million as the latest value for Q3 2024.

  • Quarterly Notes Payables changed N/A to $48.2 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Sep 2024, changed N/A year-over-year, with the annual reading at $24.6 million for FY2019, N/A changed from the prior year.
  • Notes Payables hit $48.2 million in Q3 2024 for Immunocore Holdings, up from $24.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $48.2 million in Q3 2024 to a low of $48.2 million in Q3 2024.